"Compared with ibrutinib, the efficacy [of second-generation BTK inhibitors] is [slightly improved]; however, we go more by the safety profile [in clinical decision-making]. When we use second-generation BTK inhibitors, patients have fewer problems [and adverse effects]. " Ibrutinib was the only first-generation BTK inhibitor FDA approved for patients with relapsed/refractory CLL in 2014 and first-line CLL in 2016 . The goal of these second-generation BTK inhibitors was to inhibit the BTK site more tightly while having fewer off-target effects than ibrutinib. Khan concluded that patients are likely to receive benefit from BTK inhibitors for a longer duration when second-generation drugs are utilized.